Compare RFL & IGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | RFL | IGI |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Investment Managers |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.6M | 96.4M |
| IPO Year | 2017 | 2009 |
| Metric | RFL | IGI |
|---|---|---|
| Price | $3.16 | $16.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 294.9K | 15.9K |
| Earning Date | 06-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $917,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 43.96 | N/A |
| 52 Week Low | $1.12 | $15.78 |
| 52 Week High | $2.95 | $17.09 |
| Indicator | RFL | IGI |
|---|---|---|
| Relative Strength Index (RSI) | 80.07 | 54.44 |
| Support Level | $1.22 | $15.86 |
| Resistance Level | N/A | $16.41 |
| Average True Range (ATR) | 0.34 | 0.13 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 99.33 | 55.53 |
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.